1
|
Lin H, Liu J, Hou Y, Yu Z, Hong J, Yu J, Chen Y, Hu J, Xia D. Microneedle patch with pure drug tips for delivery of liraglutide: pharmacokinetics in rats and minipigs. Drug Deliv Transl Res 2024:10.1007/s13346-024-01582-1. [PMID: 38619705 DOI: 10.1007/s13346-024-01582-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/16/2024] [Indexed: 04/16/2024]
Abstract
Transdermal delivery of peptide drugs is almost impossible with conventional penetration enhancers because of epidermal barrier function. Microneedle (MN) patches can bypass the epidermal barrier and have been developed for trans- and intradermal delivery of peptide drugs and vaccines. However, dissolving MN patches are limited by low drug loading capacities due to their small size and admixture of drug and water-soluble excipients. Furthermore, few in vivo pharmacokinetic studies, especially in large animals such as pigs, have been performed to assess post-application systemic drug exposure. Here, we developed a dissolving MN patch with pure liraglutide at the needle tips. The MN patch could load up to 2.21 ± 0.14 mg of liraglutide in a patch size of 0.9 cm2, which was nearly two orders of magnitude higher than that obtained with conventional MN patches of the same size. Raman imaging confirmed that liraglutide was localized at the MN tips. The MN had sufficient mechanical strength to penetrate the epidermis and could deliver up to 0.93 ± 0.04 mg of liraglutide into skin with a dosing variability of less than 6.8%. The MN patch delivery enabled faster absorption of liraglutide than that provided by subcutaneous (S.C.) injection, and achieved relative bioavailability of 69.8% and 46.3% compared to S.C. injection in rats and minipigs, respectively. The MN patch also exhibited similar patterns of anti-hyperglycemic effect in diabetic rats and individual variability in pharmacokinetic parameters as S.C. injection. The liraglutide MN application was well tolerated; no skin irritation was observed in minipigs except for mild erythema occurring within 4 h after once daily administration for 7 days at the same site. Our preclinical study suggests that MN patch with pure drug needle tips might offer a safe and effective alternative to S.C. injection for administration of liraglutide.
Collapse
Affiliation(s)
- Hongbing Lin
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China
| | - Jinbin Liu
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China
| | - Yulin Hou
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China
| | - Zhiyan Yu
- Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan, China
| | - Juan Hong
- Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan, China
| | - Jianghong Yu
- Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan, China
| | - Yu Chen
- Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan, China
| | - Jingwen Hu
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China
| | - Dengning Xia
- School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
| |
Collapse
|
2
|
Alsaedi MK, Lone O, Nejad HR, Das R, Owyeung RE, Del-Rio-Ruiz R, Sonkusale S. Soft Injectable Sutures for Dose-Controlled and Continuous Drug Delivery. Macromol Biosci 2024; 24:e2300365. [PMID: 37840462 DOI: 10.1002/mabi.202300365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 09/30/2023] [Indexed: 10/17/2023]
Abstract
Transdermal drug delivery offers a promising alternative to traditional methods such as oral ingestion and hypodermic injection. Hypodermic injections are painful, while oral ingestion requires higher doses due to enzymatic degradation and poor absorption. While microneedles address the pain issue, they are limited to delivering small amounts of drugs and can be impractical due to peeling off with motion and sweat. Herein, this work proposes soft injectables using drug-carrying sutures for painless and localized sustained delivery in the dermis. These sutures can remain in place during delivery and are suitable for all skin types. Surgical sutures can also serve as open capillary microfluidic channels carrying drug from a wearable drug reservoir to enable long-term (weeks to months) transdermal drug delivery. The experiments focus on delivering 5-fluorouracil (5-FU), a cancer drug, and rhodamine B, a drug model. A fixed-length suture of 60 cm delivers 0.43 mg of 5-flurouracil in 15 min. The experiments also demonstrate a continuous drug delivery of rhodamine B for over 8 weeks at a rate of 0.0195 mL h-1 . The results highlight that soft injectable sutures are promising candidates for long-term sustained delivery of varying quantities of drugs over weeks period compared to hypodermic injection, oral ingestion, or microneedles.
Collapse
Affiliation(s)
- Mossab K Alsaedi
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- Department of Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, USA
| | - Omar Lone
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- School of Engineering, Zurich University of Applied Sciences, Winterthur, 8400, Switzerland
| | - Hojatollah Rezaei Nejad
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- Department of Electrical and Computer Engineering, Tufts University, Medford, MA, 02155, USA
- Anodyne Nanotech, Inc, Boston, MA, 02118, USA
| | - Riddha Das
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- Department of Electrical and Computer Engineering, Tufts University, Medford, MA, 02155, USA
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA
| | - Rachel E Owyeung
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- Department of Electrical and Computer Engineering, Tufts University, Medford, MA, 02155, USA
| | - Ruben Del-Rio-Ruiz
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- Department of Electrical and Computer Engineering, Tufts University, Medford, MA, 02155, USA
| | - Sameer Sonkusale
- Nano Lab, Advanced Technology Laboratory, Tufts University, Medford, MA, 02155, USA
- Department of Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, USA
- Department of Electrical and Computer Engineering, Tufts University, Medford, MA, 02155, USA
- Department of Biomedical Engineering, Tufts University, Medford, MA, 02155, USA
| |
Collapse
|
3
|
Chu F, Liang L, Chen F. Effect of budesonide combined with montelukast sodium on pulmonary function parameters and immunoglobulin levels in children with bronchial asthma. Allergol Immunopathol (Madr) 2023; 51:151-157. [PMID: 37422792 DOI: 10.15586/aei.v51i4.897] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 05/15/2023] [Indexed: 07/11/2023]
Abstract
BACKGROUND AND AIM Bronchial asthma is a prevalent type of respiratory disease that affects a large proportion of pediatric patients. The purpose of this study is to further investigate the clinical effects of budesonide combined with montelukast sodium in treating bronchial asthma. METHODS Eighty six children with bronchial asthma were equally divided into study and control groups via randomized double-blind controlled trial. The control group was treated with aerosol inhalation of budesonide combined with placebo, while the study group was treated with budesonide combined with montelukast sodium. Pulmonary function parameters, immunoglobulin, and recovery of related symptoms, along with the adverse reaction rate, were observed and compared between both groups. RESULTS Before treatment, there was no marked difference in pulmonary function parameters and immunoglobulin indexes between both groups (P > 0.05). All pulmonary function indicators and immunoglobulin indexes in both groups improved following therapy, with the study group outperforming the control group (P < 0.05). The recovery time of related symptoms in the study group was shorter than that in the control group (P < 0.05). The incidence of adverse reactions in both groups was compared, with notable differences (P < 0.05). CONCLUSION Budesonide combined with montelukast sodium in the treatment of bronchial asthma has the value of clinical application and promotion.
Collapse
Affiliation(s)
- Fangfang Chu
- Department of Pediatric Respiratory, Anhui Provincial Children's Hospital, Hefei City, Anhui Province, 230051, China
| | - Lei Liang
- Department of Pediatric Respiratory, Anhui Provincial Children's Hospital, Hefei City, Anhui Province, 230051, China;
| | - Fuzhe Chen
- Department of Pediatric Respiratory, Anhui Provincial Children's Hospital, Hefei City, Anhui Province, 230051, China
| |
Collapse
|
5
|
Ahmad A. Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma. Life (Basel) 2022; 12:life12040596. [PMID: 35455087 PMCID: PMC9032250 DOI: 10.3390/life12040596] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Revised: 04/08/2022] [Accepted: 04/15/2022] [Indexed: 12/22/2022] Open
Abstract
With a high prevalence globally, asthma is a severe hazard to human health, as well as an economic and social burden. There are now novel therapies available for asthma with the use of nanotechnology. Recent developments in nanoscience and medicine have encouraged the creation of inhalable nanomedicines that can enhance the efficacy, patient compliance, and life quality for sufferers of asthma. Nanocarriers for asthma therapy, including liposomes, micelles, polymers, dendrimers, and inorganics, are presented in depth in this study as well as the current research status of these nanocarriers. Aerosolized nanomaterial-based drug transport systems are currently being developed, and some examples of these systems, as well as prospective future paths, are discussed. New research subjects include nano-modification of medicines and the development of innovative nano-drugs. Clinical experiments have proven that nanocarriers are both safe and effective. Before nanotherapy can be applied in clinical practice, several obstacles must be addressed. We look at some of the most recent research discoveries in the subject of nanotechnology and asthma therapy in this article.
Collapse
Affiliation(s)
- Aftab Ahmad
- Health Information Technology Department, Faculty of Applied Studies, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| |
Collapse
|